enVVeno Medical (NVNO) Expected to Post Earnings on Friday

enVVeno Medical (NASDAQ:NVNO) is expected to be posting its results before the market opens on Friday, October 30th. Analysts expect enVVeno Medical to announce earnings of ($3.27) per share and revenue of $2.25 million for the quarter.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($5.37) earnings per share for the quarter, missing the consensus estimate of ($4.69) by ($0.68). On average, analysts expect enVVeno Medical to post ($16.19) EPS for the current fiscal year and ($6.22) EPS for the next fiscal year.

enVVeno Medical Stock Performance

NVNO opened at $6.74 on Thursday. The company has a 50-day moving average of $9.11 and a 200-day moving average of $10.38. The company has a market capitalization of $4.65 million, a P/E ratio of -0.35 and a beta of 1.29. enVVeno Medical has a 1-year low of $6.52 and a 1-year high of $26.25.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on NVNO shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enVVeno Medical in a research report on Friday, September 25th. Zacks Research raised enVVeno Medical to a “hold” rating in a report on Tuesday, July 7th. Wall Street Zen raised enVVeno Medical to a “hold” rating in a report on Saturday, October 24th. Finally, LADENBURG THALM/SH SH upgraded enVVeno Medical from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

enVVeno Medical Company Profile

enVVeno Medical Corporation (NASDAQ:NVNO) is a late-stage medical device company focused on developing bioprosthetic, or tissue-based, treatments for venous disease. Its primary focus is chronic venous insufficiency, a condition in which damaged or absent valves allow blood to flow backward in the veins and can cause swelling, pain, skin changes and ulcers.

The company’s lead product is the VenoValve, a surgically implanted bioprosthetic valve designed to restore one-way blood flow in the deep veins of the leg.